Quest Diagnostics Incorporated (DGX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Quest Diagnostics Incorporated ("Quest" or the "Company") (NYSE: DGX). Investors who purchased Quest securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Quest and certain of its officers and/or directors have violated federal securities laws.
On January 1, 2022, the New York Times published an article regarding the efficacy of Quest and other screening labs for certain prenatal tests, reporting that Quest’s tests yield misleading results and that the Company does not accurately disclose the chances of receiving a false positive test result. On this news, Quest’s stock price fell $8.66 per share, or 5.01%, to close at $164.35 per share on January 3, 2022.
If you are aware of any facts relating to this investigation or purchased Quest shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.